Review



invivomab anti mouse cd3 ε  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Bio X Cell invivomab anti mouse cd3 ε
    (A) On day 5 after PyMG administration, mice received isotype control, <t>anti-CD3</t> alone, anti-CD28 alone, or dual <t>anti-CD3</t> and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. </p/> (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.
    Invivomab Anti Mouse Cd3 ε, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 237 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd3+%CE%B5/pmc10578141-109-0-7?v=Bio+X+Cell
    Average 97 stars, based on 237 article reviews
    invivomab anti mouse cd3 ε - by Bioz Stars, 2026-08
    97/100 stars

    Images

    1) Product Images from "Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control"

    Article Title: Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control

    Journal: Cell reports

    doi: 10.1016/j.celrep.2023.113047

    (A) On day 5 after PyMG administration, mice received isotype control, anti-CD3 alone, anti-CD28 alone, or dual anti-CD3 and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. </p/> (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.
    Figure Legend Snippet: (A) On day 5 after PyMG administration, mice received isotype control, anti-CD3 alone, anti-CD28 alone, or dual anti-CD3 and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies.

    (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.

    Techniques Used: Control, Blocking Assay, Expressing, Ex Vivo, MANN-WHITNEY


    Figure Legend Snippet:

    Techniques Used: Control, Virus, Recombinant, Staining, Cell Isolation, Blocking Assay, Negative Control, Cloning, Generated, Sequencing, Plasmid Preparation, Transgenic Assay, Software



    Similar Products

    invivomab anti mouse cd3 ε  (Bio X Cell)
    97
    Bio X Cell invivomab anti mouse cd3 ε
    (A) On day 5 after PyMG administration, mice received isotype control, <t>anti-CD3</t> alone, anti-CD28 alone, or dual <t>anti-CD3</t> and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. </p/> (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.
    Invivomab Anti Mouse Cd3 ε, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd3+%CE%B5/pmc10578141-109-0-7?v=Bio+X+Cell
    Average 97 stars, based on 1 article reviews
    invivomab anti mouse cd3 ε - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    be0015 5 rrid ab 1107628 invivomab anti mouse cd3 ε  (Bio X Cell)
    96
    Bio X Cell be0015 5 rrid ab 1107628 invivomab anti mouse cd3 ε
    (A) On day 5 after PyMG administration, mice received isotype control, <t>anti-CD3</t> alone, anti-CD28 alone, or dual <t>anti-CD3</t> and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. </p/> (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.
    Be0015 5 Rrid Ab 1107628 Invivomab Anti Mouse Cd3 ε, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd3+%CE%B5/pm37651234-321-49-57?v=Bio+X+Cell
    Average 96 stars, based on 1 article reviews
    be0015 5 rrid ab 1107628 invivomab anti mouse cd3 ε - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    cd3 ε f ab 2 fragment  (Bio X Cell)
    93
    Bio X Cell cd3 ε f ab 2 fragment
    (A) On day 5 after PyMG administration, mice received isotype control, <t>anti-CD3</t> alone, anti-CD28 alone, or dual <t>anti-CD3</t> and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. </p/> (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.
    Cd3 ε F Ab 2 Fragment, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/invivomab+anti+mouse+cd3+%CE%B5/pmc05588763-51-0-8?v=Bio+X+Cell
    Average 93 stars, based on 1 article reviews
    cd3 ε f ab 2 fragment - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) On day 5 after PyMG administration, mice received isotype control, anti-CD3 alone, anti-CD28 alone, or dual anti-CD3 and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. </p/> (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.

    Journal: Cell reports

    Article Title: Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control

    doi: 10.1016/j.celrep.2023.113047

    Figure Lengend Snippet: (A) On day 5 after PyMG administration, mice received isotype control, anti-CD3 alone, anti-CD28 alone, or dual anti-CD3 and anti-CD28 antibodies. Cell proliferation of CD4 SMARTA T TS cells in dLN was analyzed on day 8. (B and C) FoxP3-DTR mice were treated on days 0 and 2 with DT, and on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies.

    (B) Expression of FoxP3 and Bcl6 by SMARTA cells. Bar graphs show the frequency (left) and number (right) of FoxP3+ SMARTA cells. (C) Cytokine production by CD4 SMARTA T TS cells after ex vivo restimulation. (D–H) FoxP3-DTR mice were treated on days 0 and 2 with PBS or DT; and/or on days 0, 2, and 5 with CTLA4-blocking or isotype antibodies. Analysis was performed on dLN SMARTA T TS cells on day 8 after PyMG administration. (D) UMAP plots show Seurat clustering (resolution 0.3) of CD4 SMARTA T TS cells s in each condition. Bar graph depicts the proportion of each cluster. The numbers in the stacked bar graphs indicate the cluster. (E) Monocle trajectory analysis overlaid onto the Seurat clustered UMAP (all conditions combined). (F–H) IPA pathways enrichment scoring of the indicated clusters. All pathways are significant with a p value < 0.05. For (A)–(C), the data represent three independent experiments with at least five mice per group. Error bars indicate SD. Significance is determined by Mann-Whitney U test. *p < 0.05.

    Article Snippet: InVivoMab anti-mouse CD3 ε (Clone 145-2C11) , BioXcell , Cat# BE0001-1, RRID:AB_1107634.

    Techniques: Control, Blocking Assay, Expressing, Ex Vivo, MANN-WHITNEY

    Journal: Cell reports

    Article Title: Molecular, metabolic, and functional CD4 T cell paralysis in the lymph node impedes tumor control

    doi: 10.1016/j.celrep.2023.113047

    Figure Lengend Snippet:

    Article Snippet: InVivoMab anti-mouse CD3 ε (Clone 145-2C11) , BioXcell , Cat# BE0001-1, RRID:AB_1107634.

    Techniques: Control, Virus, Recombinant, Staining, Cell Isolation, Blocking Assay, Negative Control, Cloning, Generated, Sequencing, Plasmid Preparation, Transgenic Assay, Software